These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32248765)

  • 1. Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.
    Villalaín C; Herraiz I; Valle L; Mendoza M; Delgado JL; Vázquez-Fernández M; Martínez-Uriarte J; Melchor Í; Caamiña S; Fernández-Oliva A; Villar OP; Galindo A
    J Am Heart Assoc; 2020 Apr; 9(7):e015548. PubMed ID: 32248765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia.
    Stolz M; Zeisler H; Heinzl F; Binder J; Farr A
    Pregnancy Hypertens; 2018 Jan; 11():54-60. PubMed ID: 29523274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing.
    Espinoza J; Calsavara VF; Kilpatrick S; Rana S; Costantine MM; Boggess K; Wylie BJ; Moore Simas TA; Louis JM; Gaw SL; Murtha A; Wiegand S; Gollin Y; Singh D; Silver RM; Durie DE; Panda B; Norwitz ER; Burd I; Plunkett B; Scott RK; Lemoine E; Thadhani R; Karumanchi SA
    Am J Obstet Gynecol; 2024 Sep; 231(3):363.e1-363.e11. PubMed ID: 38825028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does a sFlt-1/PlGF ratio result > 655 before 34 weeks' gestation necessitate preterm delivery within 2 days? A retrospective observational study.
    Siepen C; Brennecke S
    J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2371047. PubMed ID: 38926094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.
    Bednarek-Jędrzejek M; Kwiatkowski S; Ksel-Hryciów J; Tousty P; Nurek K; Kwiatkowska E; Cymbaluk-Płoska A; Torbé A
    J Perinat Med; 2019 Sep; 47(7):732-740. PubMed ID: 31339858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study.
    Dröge LA; Perschel FH; Stütz N; Gafron A; Frank L; Busjahn A; Henrich W; Verlohren S
    Hypertension; 2021 Feb; 77(2):461-471. PubMed ID: 33280406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
    Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
    Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction.
    Herraiz I; Quezada MS; Rodriguez-Calvo J; Gómez-Montes E; Villalaín C; Galindo A
    Ultrasound Obstet Gynecol; 2018 Nov; 52(5):631-638. PubMed ID: 28876491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. sFlt-1/PlGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow.
    Quezada MS; Rodríguez-Calvo J; Villalaín C; Gómez-Arriaga PI; Galindo A; Herraiz I
    Ultrasound Obstet Gynecol; 2020 Oct; 56(4):549-556. PubMed ID: 31840879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study.
    Herraiz I; Simón E; Gómez-Arriaga PI; Quezada MS; García-Burguillo A; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2018 Jul; 13():279-285. PubMed ID: 30177066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
    Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
    Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
    Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
    Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.
    Stepan H; Hund M; Andraczek T
    Hypertension; 2020 Apr; 75(4):918-926. PubMed ID: 32063058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia.
    Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dinkel C; Schoedl M; Dilba P; Hund M; Verlohren S
    Obstet Gynecol; 2016 Aug; 128(2):261-269. PubMed ID: 27399996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of angiogenic markers in pregnancy with fetal growth restriction.
    Palmrich P; Kalafat E; Pateisky P; Schirwani-Hartl N; Haberl C; Herrmann C; Khalil A; Binder J
    Ultrasound Obstet Gynecol; 2024 May; 63(5):619-626. PubMed ID: 37774098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.
    Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC
    Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.